Oreja-Guevara Celia, Kobelt Gisela, Berg Jenny, Capsa Daniela, Eriksson Jennifer
Department of Neurology, IdISSC, Hospital Universitario Clinico San Carlos, Madrid, Spain.
European Health Economics, Mulhouse, France.
Mult Scler. 2017 Aug;23(2_suppl):166-178. doi: 10.1177/1352458517708672.
In order to estimate the value of interventions in multiple sclerosis (MS) where lifetime costs and outcomes cannot be observed, outcome data have to be combined with costs. This requires that cost data be regularly updated.
This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015.
A total of 462 patients (mean age 43 years) participated in Spain; 96% were below retirement age and of these, 45% were employed. Employment was related to disability, and MS affected productivity at work for 72% of those working. Overall, 92% and 64% of patients experienced fatigue and cognitive difficulties as a problem, respectively. Mean utility and total annual costs were estimated at 0.772 and €20,600 at Expanded Disability Status Scale (EDSS) 0-3, 0.486 and €48,500 at EDSS 4-6.5 and 0.182 and €68,700 at EDSS 7-9, respectively. The mean cost of a relapse was €2050.
This study illustrates the burden of MS on Spanish patients and provides current data that are important for development of health policies.
为了评估终身成本和结局无法观察到的多发性硬化症（MS）干预措施的价值，结局数据必须与成本相结合。这就要求定期更新成本数据。
本研究是一项在16个国家开展的横断面回顾性研究的一部分，收集了MS患者的资源消耗、工作能力、健康相关生活质量（HRQoL）和常见症状的数据。从社会角度，按严重程度水平以2015年欧元呈现描述性分析结果。
西班牙共有462名患者（平均年龄43岁）参与研究；96%未达到退休年龄，其中45%为就业状态。就业与残疾有关，MS影响了72%在职患者的工作生产力。总体而言，分别有92%和64%的患者将疲劳和认知困难视为问题。在扩展残疾状态量表（EDSS）0 - 3级时，平均效用和年度总成本估计分别为0.772和20,600欧元；在EDSS 4 - 6.5级时，分别为0.486和48,500欧元；在EDSS 7 - 9级时，分别为0.182和68,700欧元。复发的平均成本为2050欧元。
本研究说明了MS给西班牙患者带来的负担，并提供了对卫生政策制定很重要的当前数据。
